We came across a bullish thesis on Exelixis, Inc. on Business Invest’s Substack by Francesco Ferrari. In this article, we will summarize the bulls’ thesis on EXEL. Exelixis, Inc.’s share was trading at $44.08 as of January 13th. EXEL’s trailing and forward P/E were 18.52 and 15.24 respectively according to Yahoo Finance.
Photo by National Cancer Institute on Unsplash
Exelixis (EXEL) is a biopharmaceutical company focused on the discovery, development, and commercialization of...
